Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $9.00 price target on shares of Trevena in a research report on Tuesday, April 2nd.

Trevena Price Performance

Shares of NASDAQ TRVN opened at $0.39 on Friday. Trevena has a 1 year low of $0.30 and a 1 year high of $3.28. The company has a debt-to-equity ratio of 8.35, a current ratio of 4.66 and a quick ratio of 4.66. The company’s 50-day moving average is $0.52 and its 200 day moving average is $0.59. The stock has a market capitalization of $7.20 million, a P/E ratio of -0.13 and a beta of 1.10.

Hedge Funds Weigh In On Trevena

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in Trevena by 51.8% in the first quarter. Renaissance Technologies LLC now owns 70,532 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 24,080 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Trevena in the fourth quarter worth about $40,000. Jane Street Group LLC grew its holdings in Trevena by 166.2% in the first quarter. Jane Street Group LLC now owns 45,330 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 28,303 shares during the period. Jump Financial LLC purchased a new stake in Trevena in the third quarter worth about $27,000. Finally, Virtu Financial LLC purchased a new stake in Trevena in the second quarter worth about $70,000. Hedge funds and other institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.